Imagine a smoke detector for the body that catches a fire before it spreads. Instead of waiting for symptoms or using expensive scans that often miss early signs, this tool uses a simple blood test to find specific protein signals. It's designed specifically for people who have a family history of the disease, giving them a fighting chance through early surgery.
Pancreatic cancer is usually detected too late for cure, with 85% of cases identified beyond the point of surgical intervention. Current biomarkers like CA19-9 lack the sensitivity and specificity needed for reliable early screening.
A 5-plex multiple immunoassay blood test that provides a probability score for pancreatic cancer and a pilot screening program for high-risk individuals.
If you are a diagnostic company dealing with the low accuracy of CA19-9 tests — this project developed a 5-plex multiple immunoassay that provides a probability score for pancreatic cancer. It offers >91% sensitivity and >96% specificity, significantly improving detection rates.
If you are a clinic owner dealing with the high cost and limited availability of imaging for screening — this project developed a blood-based test to identify high-risk individuals. This allows for earlier surgical intervention, which can increase survival rates to 42%.
If you are a government health body dealing with a 5-year survival rate of less than 10% for pancreatic cancer — this project developed a validated screening program. It aims to increase the European 5-year survival rate to 30% by 2035.
Based on available project data, the specific price per test is not disclosed.
The test has already been used in studies with over 450 samples and is now moving into a prospective multi-center study across seven EU countries to validate clinical performance.
The test was developed by the partner Reccan; however, specific licensing terms are not provided in the project data.
The project involves collaboration with national screening authorities to integrate the test into existing programs and pilot programs in Greece, Slovenia, and Lithuania.
The project runs from 2025-05-01 to 2029-04-30, with a long-term goal of impacting survival rates by 2035.
The consortium is heavily weighted toward commercial application, with 12 industry partners (44% of the total) and 8 SMEs. This strong industrial presence, combined with 5 universities and 4 research centers across 13 countries, suggests a high focus on market translation rather than pure academic research.
Contact Univerzitetni klinicni center Maribor in Slovenia
Contact us to explore licensing opportunities with Reccan or partnership options within the SHIELD consortium.
